Floatz logo

Dilanubicel

Acute Leukemia of Ambiguous Lineage

Nohla Therapeutics, Inc.Cell therapyPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
73/ 100

Competitive context

46 Active assets in the Acute Leukemia of Ambiguous Lineage cohort.

Asset / SponsorPhaseRating
L-Ofloxacin
Children's Oncology Group
Phase 3BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
Cytosin-Arabinosid
SWOG Cancer Research Network
Phase 2B
METHOTREXATE
SWOG Cancer Research Network
Phase 2B
VINCRISTINE SULFATE
Children's Oncology Group
Phase 2B

View all 50 →

Same molecule, other indications

Dilanubicel is also rated in:

acute myeloid leukemia, del(5q31-q32)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →